Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy.

Noori N, Tabibi H, Hosseinpanah F, Hedayati M, Nafar M.

Int J Vitam Nutr Res. 2013;83(2):77-85. doi: 10.1024/0300-9831/a000147.

PMID:
24491880
2.

Effects of ginger on serum glucose, advanced glycation end products, and inflammation in peritoneal dialysis patients.

Imani H, Tabibi H, Najafi I, Atabak S, Hedayati M, Rahmani L.

Nutrition. 2015 May;31(5):703-7. doi: 10.1016/j.nut.2014.11.020. Epub 2014 Dec 20.

PMID:
25837216
3.
4.

Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.

Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE; AGE-less Study Group.

Clin J Am Soc Nephrol. 2015 May 7;10(5):759-66. doi: 10.2215/CJN.07750814. Epub 2015 Feb 20.

5.

Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.

Daimon M, Ono Y, Saito T, Yamaguchi H, Hirata A, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Kato T.

Diabetes Care. 1999 May;22(5):877-8. No abstract available.

6.

Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.

J Diabetes Complications. 2003 Jan-Feb;17(1):16-21.

PMID:
12505751
7.

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group.

Am J Nephrol. 2004 Jan-Feb;24(1):32-40. Epub 2003 Dec 17.

PMID:
14685005
8.

Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study.

Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP.

Diabetes Res Clin Pract. 2001 Jun;52(3):175-83.

PMID:
11323087
9.

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).

Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, Stein G, Müller UA.

J Diabetes Complications. 2003 Mar-Apr;17(2):90-7.

PMID:
12614975
10.
11.

Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy.

Raj DS, Lim G, Levi M, Qualls C, Jain SK.

Am J Kidney Dis. 2004 Jan;43(1):154-60.

PMID:
14712439
12.

The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.

Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H.

Metabolism. 2000 Aug;49(8):1030-5.

PMID:
10954022
13.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
14.

Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.

Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M.

Diab Vasc Dis Res. 2013 May;10(3):239-45. doi: 10.1177/1479164112460253. Epub 2012 Oct 22.

PMID:
23091285
15.

Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.

Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.

Nephrology (Carlton). 2008 Dec;13(6):517-21. doi: 10.1111/j.1440-1797.2008.00929.x. Epub 2008 Mar 17.

PMID:
18363646
16.

Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K.

J Am Soc Nephrol. 1998 Sep;9(9):1681-8.

17.

Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.

Sebeková K, Gazdíková K, Syrová D, Blazícek P, Schinzel R, Heidland A, Spustová V, Dzúrik R.

J Hum Hypertens. 2003 Apr;17(4):265-70.

PMID:
12692571
18.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

19.

Daily haemodialysis improves indices of protein glycation.

Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U.

Nephrol Dial Transplant. 2002 May;17(5):871-8.

PMID:
11981076
20.

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.

Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, Thorpe SR, Baynes JW, Reiter R.

Diabetes Res Clin Pract. 1999 Feb;43(2):81-9.

PMID:
10221660

Supplemental Content

Support Center